Neurodegenerative disease profoundly affects structures and pathways responsible for memory, cognition, and higher-order ...

Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or ...

Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements ...

The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of ...

We report the cases of 3 patients with biopsy-proven light-chain cardiac amyloidosis (AL-CA) presenting with varying clinical manifestations and abnormal findings on Tc-based bone-avid scintigraphy, ...

In this study, we aimed to quantify the impact of data-driven motion-correction reconstruction for PET imaging on still and motion-corrupted 18F-FDG PET brain scans of children and adolescents.

The growing demand for amyloid and tau PET imaging, driven by new dementia therapies and biomarker-based diagnosis, has increased the need for accessible PET brain imaging in outpatient neurology ...

Neurodegenerative diseases are characterized by progressive neuronal dysfunction, synaptic loss, and decline in cognitive, behavioral, or motor function. Understanding these disorders requires a ...

PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape ...

The past year has marked a period of significant growth, collaboration, and strategic investment for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS), with a ...